Dyne Therapeutics Inc [NASDAQ: DYN] traded at a low on 2025-11-06, posting a -12.89 loss after which it closed the day’ session at $18.2.
The results of the trading session contributed to over 5271437 shares changing hands. Over the past one week, the price volatility of Dyne Therapeutics Inc stands at 11.40% while the volatility over the past one month is 6.76%.
The market cap for DYN stock reached $2.59 billion, with 142.61 million shares outstanding and 109.62 million shares in the current float. Compared to the average trading volume of 2.80M shares, DYN reached a trading volume of 5271437 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Dyne Therapeutics Inc [DYN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DYN shares is $35.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DYN stock is a recommendation set at 1.41. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Dyne Therapeutics Inc shares, keeping their opinion on the stock as Perform, with their previous recommendation back on October 10, 2025. The new note on the price target was released on August 25, 2025, representing the official price target for Dyne Therapeutics Inc stock. Previously, the target price had yet another raise to $13, while Bernstein analysts kept a Mkt Perform rating on DYN stock.
The Price to Book ratio for the last quarter was 3.75, with the Price to Cash per share for the same quarter was set at 5.57.
How has DYN stock performed recently?
Dyne Therapeutics Inc [DYN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.70. With this latest performance, DYN shares gained by 25.03% in over the last four-week period, additionally plugging by 61.18% over the last 6 months – not to mention a drop of -22.73% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DYN stock in for the last two-week period is set at 49.13, with the RSI for the last a single of trading hit 1.90, and the three-weeks RSI is set at 1.43 for Dyne Therapeutics Inc [DYN]. The present Moving Average for the last 50 days of trading for this stock 15.56, while it was recorded at 21.46 for the last single week of trading, and 12.52 for the last 200 days.
Dyne Therapeutics Inc (DYN) Capital Structure & Debt Analysis
According to recent financial data for Dyne Therapeutics Inc. ( DYN), the Return on Equity (ROE) stands at -60.66%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -51.81%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Dyne Therapeutics Inc’s Return on Invested Capital (ROIC) is -52.50%, showcasing its effectiveness in deploying capital for earnings.
Dyne Therapeutics Inc (DYN) Efficiency & Liquidity Metrics
Based on Dyne Therapeutics Inc’s (DYN) latest financial statements, the Debt-to-Equity Ratio is 0.17%, indicating its reliance on debt financing relative to shareholder equity.
Dyne Therapeutics Inc (DYN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Dyne Therapeutics Inc. (DYN) effectively leverages its workforce, generating an average of -$2218848.17 per employee. The company’s liquidity position is robust, with a Current Ratio of 13.47% and a Quick Ratio of 13.47%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Dyne Therapeutics Inc [DYN]
With the latest financial reports released by the company, Dyne Therapeutics Inc posted -0.88/share EPS, while the average EPS was predicted by analysts to be reported at -0.91/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.03. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DYN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Dyne Therapeutics Inc go to 3.74%.
Insider trade positions for Dyne Therapeutics Inc [DYN]
There are presently around $95.36%, or 95.83%% of DYN stock, in the hands of institutional investors. The top three institutional holders of DYN stocks are: ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with ownership of 8.02 million shares, which is approximately 8.6697%. FCPM III SERVICES B.V., holding 7.85 million shares of the stock with an approximate value of $$276.86 million in DYN stocks shares; and FCPM III SERVICES B.V., currently with $$260.69 million in DYN stock with ownership which is approximately 7.9853%.
